Inflection Biosciences’ panel of advisors, comprising leading physicians and scientific leaders in the field of oncology along with technical, business and regulatory experts, has been assembled to strategically support development of the company’s innovative pipeline.
Dr Martin Page - Cancer Biologist and drug development
Dr Martin Page has over 30 years experience in Oncology R&D within Biotech and Pharmaceutical companies. From 2005-2011 he worked for Johnson & Johnson Pharmaceuticals where he was Vice President, Global Head of Oncology Research managing the small molecule and monoclonal antibody pipelines across Europe and USA. Prior to this he was Senior Director of Cancer Biology at OSI Pharmaceuticals, Director of Biology at Oxford GlycoSciences, and Oncology Therapeutic Head for Europe in Glaxo-Wellcome. Through his leadership, Martin has taken multiple Oncology preclinical IND candidates into clinical trials. In addition to managing Oncology R&D pipelines, Martin understands and deploys the integration of Translational Research and Biomarker technologies into their Development paths. Since 2011 he has taken a new role as an independent Oncology Scientific Consultant working with investment/venture capital companies, Biotechs and CROs.
Professor Funda Meric Bernstam - Oncology therapeutic development
Funda Meric-Bernstam is the Chair of the Department of Investigational Cancer Therapeutics - the Phase I Program at MD Anderson Cancer Center, the Medical Director of the Institute for Personalized Cancer Therapy (IPCT), and Professor in the Divisions of Cancer Medicine and Surgery at MD Anderson Cancer Center, Houston, Texas. She has a basic and translational research program that is focused on molecular therapeutics, predominantly focused on PI3K/Akt/mTOR signaling, to delineate the mechanism of action of each agent targeting this pathway and the molecular alterations useful to prospectively identify patients who will benefit most from each agent, and optimal combination therapies.
She has participated in, as well as led, trials including investigator-initiated trials, cooperative group trials, and industry sponsored trials. These trials have ranged from a window of opportunity trials, neoadjuvant therapy trials, a Phase I and II trials in the advanced cancer setting as well as new surgical techniques, new imaging devices and molecular diagnostics.
Professor Josep Tabernero, MD, Ph. D. - Oncology therapeutic development
Josep Tabernero is currently the Head of the Medical Oncology Department and Head of the Gastrointestinal Tumors and Phase I Unit at the Vall d’Hebron University Hospital in Barcelona and the Director of the Vall d’Hebron Institute of Oncology. He is very actively involved in translational research and pharmacodynamic Phase I studies with molecular targeted therapies. He is especially devoted to Phase I and II studies with pharmacodynamic endpoints with novel agents directed to the membrane receptors, including PI3K and ERK signalling pathways.
Dr. Tabernero is a member of the Executive Board of the European Society for Medical Oncology (ESMO), currently holding the position of Treasurer and Chair of the Fellowships and Awards Committee. He is also member of the American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO), participating in its International Affairs Committee. He is actively involved in different editorial boards including the Journal of Clinical Oncology, Clinical Cancer Research, Cancer Discovery, Clinical Colorectal Cancer and Annals of Oncology. Dr Tabernero holds MD and PhD degrees from the Universitat Autònoma de Barcelona, Spain.
Martin Buckland - Corporate and business development
Martin Buckland has more than 30 years of commercial, corporate and business development experience in the pharmaceutical and biotechnology industries. He is currently Chief Corporate Officer of Astex Pharmaceuticals, Inc. and was responsible for negotiating many of the company's collaboration and licensing agreements, as well as the merger of Astex Therapeutics Limited with SuperGen, Inc. and the subsequent sale of the company to Otsuka Pharmaceutical. He joined Astex from Elan Pharmaceuticals, where he held the position of Vice President of Global Business Development. His prior experience includes a variety of business development and commercial management roles with Quintiles, Xenova and Celltech. He has a BA in Chemistry and a DPhil from the University of Oxford, UK, and an MBA from the Open Business School.